Xencor, Inc. (XNCR) Major Shareholder Buys $191,303.40 in Stock
Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 9,215 shares of the company’s stock in a transaction on Thursday, December 14th. The shares were bought at an average price of $20.76 per share, with a total value of $191,303.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Xencor, Inc. (NASDAQ XNCR) traded up $0.46 during trading on Thursday, reaching $21.49. The company’s stock had a trading volume of 177,000 shares, compared to its average volume of 216,280. Xencor, Inc. has a 1 year low of $18.55 and a 1 year high of $28.64.
Several research analysts have issued reports on the company. BidaskClub upgraded Xencor from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 7th. Cantor Fitzgerald assumed coverage on Xencor in a research note on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price objective for the company. Zacks Investment Research upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Piper Jaffray Companies reiterated a “buy” rating and set a $35.00 price objective on shares of Xencor in a research note on Sunday, November 12th. Finally, ValuEngine lowered Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $30.80.
Several hedge funds have recently made changes to their positions in XNCR. Dimensional Fund Advisors LP grew its holdings in shares of Xencor by 57.4% during the first quarter. Dimensional Fund Advisors LP now owns 286,894 shares of the biopharmaceutical company’s stock worth $6,863,000 after purchasing an additional 104,638 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Xencor during the first quarter worth $949,000. Bank of America Corp DE grew its holdings in shares of Xencor by 144.4% during the first quarter. Bank of America Corp DE now owns 16,199 shares of the biopharmaceutical company’s stock worth $387,000 after purchasing an additional 9,572 shares during the last quarter. Strs Ohio grew its holdings in shares of Xencor by 4.9% during the second quarter. Strs Ohio now owns 36,200 shares of the biopharmaceutical company’s stock worth $764,000 after purchasing an additional 1,700 shares during the last quarter. Finally, TD Asset Management Inc. grew its holdings in shares of Xencor by 9.3% during the second quarter. TD Asset Management Inc. now owns 81,769 shares of the biopharmaceutical company’s stock worth $1,726,000 after purchasing an additional 6,963 shares during the last quarter. Institutional investors own 77.62% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Xencor, Inc. (XNCR) Major Shareholder Buys $191,303.40 in Stock” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/14/xencor-inc-xncr-major-shareholder-buys-191303-40-in-stock.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.